Your browser is no longer supported. Please, upgrade your browser.
Settings
LOGC LogicBio Therapeutics, Inc. daily Stock Chart
LOGC [NASD]
LogicBio Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.49 Insider Own0.30% Shs Outstand25.26M Perf Week11.48%
Market Cap220.77M Forward P/E- EPS next Y-1.84 Insider Trans0.00% Shs Float16.17M Perf Month14.40%
Income-35.70M PEG- EPS next Q-0.49 Inst Own67.80% Short Float1.33% Perf Quarter-1.91%
Sales- P/S- EPS this Y-985.30% Inst Trans-4.77% Short Ratio2.41 Perf Half Y9.66%
Book/sh2.35 P/B3.72 EPS next Y-4.00% ROA-48.50% Target Price22.00 Perf Year-4.38%
Cash/sh2.50 P/C3.49 EPS next 5Y- ROE-53.00% 52W Range6.34 - 20.07 Perf YTD21.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.45% Beta-
Dividend %- Quick Ratio15.70 Sales past 5Y- Gross Margin- 52W Low37.85% ATR0.83
Employees23 Current Ratio15.70 Sales Q/Q- Oper. Margin- RSI (14)48.73 Volatility9.16% 9.08%
OptionableNo Debt/Eq0.18 EPS Q/Q-113.50% Profit Margin- Rel Volume0.67 Prev Close9.63
ShortableYes LT Debt/Eq0.18 EarningsMar 30 BMO Payout- Avg Volume88.89K Price8.74
Recom1.60 SMA20-7.14% SMA505.48% SMA200-16.36% Volume61,836 Change-9.24%
May-01-19Initiated ROTH Capital Buy $26
Feb-21-20 03:06PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC GlobeNewswire -9.24%
Feb-20-20 02:45PM  SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Feb-19-20 06:11PM  ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against LogicBio Therapeutics, Inc. LOGC GlobeNewswire +10.84%
03:00PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Feb-18-20 06:04PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC CNW Group +9.36%
04:40PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:44AM  Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Investigation of LogicBio Therapeutics, Inc. (LOGC) ACCESSWIRE
Feb-17-20 03:10PM  INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Feb-15-20 03:24PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC ACCESSWIRE
Feb-14-20 03:45PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:51PM  LOGC LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against LogicBio Therapeutics, Inc. LOGC GlobeNewswire
Feb-13-20 05:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC ACCESSWIRE
12:12PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:45AM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of LogicBio Therapeutics, Inc. (LOGC) ACCESSWIRE
Feb-12-20 08:58AM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against LogicBio Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire +14.63%
Feb-11-20 06:01PM  EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against LogicBio Therapeutics, Inc. LOGC Business Wire -31.96%
02:22PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC GlobeNewswire
10:03AM  Gene therapy startups stock stumbles after FDA questions treatment American City Business Journals
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 04:05PM  LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia GlobeNewswire -5.00%
Jan-10-20 07:05AM  LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones GlobeNewswire
07:00AM  LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome GlobeNewswire
Dec-20-19 06:21PM  Is LogicBio Therapeutics, Inc. (LOGC) A Good Stock To Buy? Insider Monkey
Dec-17-19 08:00AM  LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide Candidates GlobeNewswire
Nov-14-19 06:57AM  We're Hopeful That LogicBio Therapeutics (NASDAQ:LOGC) Will Use Its Cash Wisely Simply Wall St.
Nov-12-19 08:00AM  LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire
Nov-08-19 10:47AM  Is LogicBio Therapeutics, Inc. (LOGC) A Good Stock To Buy? Insider Monkey -5.07%
Nov-07-19 08:00AM  LogicBio Therapeutics to Present at November Conferences GlobeNewswire
Oct-16-19 08:00AM  LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress GlobeNewswire
Oct-09-19 04:15PM  Horizon Technology Finance Provides Third Quarter 2019 Portfolio Update PR Newswire
Sep-26-19 08:00AM  LogicBio Therapeutics to Present at October Conferences GlobeNewswire -5.28%
Aug-13-19 08:00AM  LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire +7.95%
May-31-19 10:58AM  Opening Bell, May 31, 2019 CNBC Videos
May-30-19 08:00AM  LogicBio to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-14-19 08:07AM  LogicBio Therapeutics: 1Q Earnings Snapshot Associated Press
08:00AM  LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates GlobeNewswire
May-13-19 06:47PM  Kamada (KMDA) to Report Q1 Earnings: What's in the Cards? Zacks
04:24PM  Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store? Zacks
Apr-29-19 08:00AM  LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia GlobeNewswire +9.17%
Apr-22-19 08:00AM  LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide Platform Development and Advancement of Lead Program into Clinic GlobeNewswire
Apr-01-19 08:19AM  LogicBio Therapeutics: 4Q Earnings Snapshot Associated Press
08:00AM  LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates GlobeNewswire
Mar-07-19 01:55PM  LogicBio planning first trial of gene editing treatment for children American City Business Journals +5.26%
Feb-25-19 07:00AM  LogicBio Therapeutics to Present at Upcoming March Conferences GlobeNewswire
Feb-22-19 07:00AM  LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development GlobeNewswire
Dec-06-18 08:00AM  LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors GlobeNewswire
Dec-03-18 08:00AM  LogicBio Reports Third Quarter 2018 Financial Results GlobeNewswire -7.70%
Nov-15-18 06:00AM  LogicBio Announces Partnership with Childrens Medical Research Institute to Develop Next Generation Viral Vectors GlobeNewswire -6.19%
Nov-13-18 08:00AM  LogicBio to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-11-18 09:10AM  The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-24-18 02:00AM  Arix Bioscience plc - LogicBio Announces Closing of Initial Public Offering PR Newswire -21.98%
Oct-23-18 04:05PM  LogicBio Therapeutics Announces Closing of Initial Public Offering GlobeNewswire -8.60%
Oct-22-18 04:00PM  Chardan Serves as Lead Manager for LogicBio Therapeutics PR Newswire
Oct-19-18 06:42AM  LogicBio's IPO: What You Need To Know Benzinga
Oct-15-18 01:10PM  IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service Benzinga
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate Lb-301 for the treatment of crigler-najjar syndrome. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.